Solara Active Pharma Sciences Limited (NSE:SOLARA) disclosed on 18 August 2026 that its Board of Directors, via circular resolution dated 17 August 2026, approved the allotment of 2,250 fully paid equity shares of face value Rs 10 each under the Solara Employee Stock Option Plan 2018, at an exercise price of Rs 375 per share.
Key Highlights
- The board allotted 2,250 equity shares under Solara Employee Stock Option Plan 2018, with an exercise price of Rs 375 per share and a premium of Rs 365 per share.
- Total money realised from the exercise of these options amounts to Rs 8,43,750, as disclosed in the filing dated 18 August 2026.
- Post-allotment, the company's total fully paid equity shares increase to 4,78,02,235, with overall paid-up share capital rising to Rs 48,05,79,964.50.
- The newly allotted shares carry ISIN INE624Z01016 and rank pari-passu with existing equity shares in all respects, with no lock-in applicable.
About the Company
Solara Active Pharma Sciences Limited (NSE:SOLARA), headquartered in Chennai, Tamil Nadu, is an active pharmaceutical ingredients (API) manufacturer operating across multiple therapeutic segments including antiretrovirals and pain management molecules. The company's manufacturing facilities serve regulated markets globally and it is listed on both the NSE and BSE. Its registered office is located in Navi Mumbai, Maharashtra.
Announcement in Detail
The Board of Directors of Solara Active Pharma Sciences Limited, through a circular resolution passed on 17 August 2026, approved the allotment of 2,250 equity shares of face value Rs 10 each, fully paid up, against the exercise of vested options under the Solara Employee Stock Option Plan 2018. The exercise price per share was fixed at Rs 375, implying a share premium of Rs 365 per share. The total consideration realised by the company from this exercise stands at Rs 8,43,750.
Of the 7,500 options granted on 28 June 2024 under the scheme, 2,250 vested and all 2,250 vested options were exercised within the 120-day exercise window stipulated under the plan. The allotment is compliant with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. Post-allotment, the diluted earnings per share, as disclosed in the filing, stands at Rs 3.67 per share.
Impact on Investors
Investors will note that the allotment of 2,250 shares represents a marginal increase in the company's issued equity capital. The total number of fully paid equity shares rises from 4,77,99,985 to 4,78,02,235, an incremental addition of 2,250 shares against a pre-allotment base of approximately 4.82 crore shares (including partly paid shares). The dilution to existing shareholders is negligible given the scale of this allotment relative to total share capital.
The filing shows that the newly issued shares rank pari-passu with all existing equity shares, carry no lock-in period, and were issued under a SEBI-compliant scheme. The disclosed diluted earnings per share of Rs 3.67 per share reflects the expanded share base post-allotment.
Sector / Market Context
India's pharmaceutical industry, particularly the API segment, has been a focus area for domestic capacity building under the government's Production Linked Incentive scheme for pharmaceuticals. Employee stock option plans are a common retention and incentive mechanism across listed pharma companies, used to align employee interests with long-term business performance. SEBI's Share Based Employee Benefits and Sweat Equity Regulations, 2021 govern the framework under which such allotments are made by listed entities in India, ensuring standardised disclosure and compliance practices across the sector.